Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari ® in the Kingdom of Saudi Arabia. This follows Emmaus’ announcement that the SFDA had granted Endari ® a priority review designation as part of its program to expedite the review of drugs that are expected to have a sign
August 18, 2020
· 4 min read